4basebio PLC Awards 684,872 Share Options to Leadership Team with Performance-Linked Vesting Conditions

4basebio's Enzymatic DNA Synthesis Technology and Market Role

Based in Cambridge, 4basebio has developed proprietary enzymatic DNA synthesis technology aimed at next-generation genetic medicine markets. Their platform produces GMP-grade synthetic DNA and mRNA with enhanced speed, purity, and scalability compared to traditional plasmid-based methods. This positions 4basebio as a key partner across therapeutic areas including gene therapies, genome editing, mRNA production, and DNA vaccines.

The company focuses on delivering application-specific DNA constructs tailored to partner needs, overcoming plasmid manufacturing limitations to accelerate proof-of-concept and clinical milestones while maintaining high safety and quality standards. This opportunity is driven by rising demand for advanced synthetic biology tools in therapeutic development, framing the executive compensation strategy.

CEO Dr. Amy Walker’s Share Option Grant and Compensation Details

Dr. Amy Walker, 4basebio’s CEO, received the largest share option grant of 387,872 options. Of these, 301,872 options have an exercise price of a35.05 (the closing mid-market price on 1 May 2026) and vest equally over four years from that date. An additional 86,000 options at the same exercise price are subject to a performance condition, exercisable only if the volume-weighted average share price exceeds a315.00 for 30 consecutive trading days.

After this grant, Dr. Walker holds 430,000 options, representing 2.77% of the company’s issued share capital. Part of her grant includes delayed awards agreed in 2024 and 2025, reflecting multi-year compensation arrangements. The performance-linked tranche aligns executive rewards with shareholder value creation by tying incentives to share price milestones.

Executive Chair Dr. Manja Boerman’s Option Award and Vesting

Dr. Manja Boerman, Executive Chair, was granted 172,000 options at a35.05 per share, representing delayed grants from 2024 and 2025. These options vest equally over four years from 1 May 2026. Post-grant, Dr. Boerman holds 172,000 options, or 1.11% of issued share capital.

Unlike the CEO’s grant, Dr. Boerman’s options have no performance conditions and vest solely on a time basis, reflecting differences in role or prior agreement terms. The four-year vesting promotes retention and sustained equity participation.

Non-Executive Director and PDMR Option Grants

Non-executive Director Dr. Heikki Lanckriet received 75,000 options at a35.05 per share, which vest immediately. He now holds 101,137 options, or 0.65% of issued share capital. Immediate vesting for a non-executive director is notable and may relate to his specific role or tenure.

Richard Bungay, a PDMR, was granted 50,000 options at a35.25 per share (closing price on 21 July 2026), vesting equally over four years from that date. He holds 50,000 options, or 0.32% of issued share capital. The later grant date and higher exercise price reflect timing differences within the overall award.

Exercise Price Determination Based on Prior Market Prices

Exercise prices were set referencing closing mid-market prices on specific dates to ensure fair valuation and regulatory compliance. Dr. Walker, Dr. Boerman, and Dr. Lanckriet’s options are priced at a35.05 (closing price on 1 May 2026), while Mr. Bungay’s are at a35.25 (closing price on 21 July 2026). This approach aligns with grant timing and prior agreements from 2024 and 2025.

The performance-linked tranche for Dr. Walker requires the share price to exceed a315.00 for 30 consecutive days, nearly triple the exercise price, signaling ambitious value creation targets embedded in executive incentives.

Dilution Impact and Total Options Outstanding After Grant

4basebio’s issued share capital stands at 15,538,518 shares. The 684,872 new options raise total options outstanding to 1,354,024, approximately 8.71% of issued capital. This dilution is material for shareholders and highlights potential future share issuance upon option exercise.

The four-year vesting schedules stagger option exercises, potentially mitigating simultaneous dilution. Investors should monitor exercise timing relative to share price milestones and market conditions.

Prior-Year Delayed Grant Agreements

Some options granted to Dr. Walker (301,872) and Dr. Boerman (172,000) were agreed in 2024 and 2025 but formally granted in July 2026. This indicates planned multi-year compensation strategies rather than reactive awards, reflecting a structured approach to retention and dilution management.

The staggered grant timing suggests the company’s intent to balance competitive executive incentives with controlled dilution over time.

Performance Condition Tied to a315.00 Share Price Target

Dr. Walker’s 86,000 options include a performance condition requiring a volume-weighted average share price above a315.00 for 30 consecutive trading days to become exercisable. This threshold is nearly three times the exercise price, representing a high-value creation benchmark.

This condition aligns management incentives with shareholder returns but is subject to market and sector factors beyond management control, serving as one element of a comprehensive incentive framework.

Regulatory Status and Inside Information Disclosure

The announcement is classified as inside information under Article 7 of EU Regulation 596/2014, as amended, indicating the grant was material non-public information prior to disclosure on 22 July 2026. The company complied with insider dealing prevention protocols.

The detailed disclosure of grantees, roles, grant dates, exercise prices, and vesting terms ensures transparency for investors and regulators. Identifying Richard Bungay as a PDMR rather than a director clarifies regulatory distinctions relevant to governance assessment.

Investor Considerations and Shareholder Dilution Outlook

Shareholders should note the material dilution from the 8.71% options pool and the concentration of the largest grant with the CEO (2.77% of issued capital), which aligns incentives but centralizes executive equity exposure.

The performance condition on Dr. Walker’s options sets a clear share price milestone to watch as a measure of strategic success. The prevalence of four-year vesting schedules indicates management retention focus and confidence in the company’s prospects.

Investors should also evaluate current share price relative to exercise prices (a35.05 to a35.25) to assess intrinsic value and incentive effectiveness.